陳信銘DDS, MS, PhD 口腔顎面外科專科醫師 台大醫院牙科部口腔顎面外科主治醫師 台大牙醫學院口腔生物科學研究所助理教授

Presentation on theme: "陳信銘DDS, MS, PhD 口腔顎面外科專科醫師 台大醫院牙科部口腔顎面外科主治醫師 台大牙醫學院口腔生物科學研究所助理教授"— Presentation transcript:

1 陳信銘DDS, MS, PhD 口腔顎面外科專科醫師 台大醫院牙科部口腔顎面外科主治醫師 台大牙醫學院口腔生物科學研究所助理教授
99年口腔黏膜健檢品質提升計畫 轉介個案處置與管理 陳信銘DDS, MS, PhD 口腔顎面外科專科醫師 台大醫院牙科部口腔顎面外科主治醫師 台大牙醫學院口腔生物科學研究所助理教授

2 轉介個案處置與管理 待確診個案轉介醫療網（依個別區域分別介紹） 口腔癌及其癌前病變處理流程 轉介常見或容易混淆之口腔癌及其癌前病變
口腔癌癌前病變治療共識與原則 口腔癌治療共識與原則 轉介個案之管理

3 待確診個案轉介醫療網

4 口腔癌確認診斷及治療醫院名單 確診醫院條件 : 口腔顎面外科或耳鼻喉科專科醫師一名及專任口腔病理科或病理專科醫師一名
確診醫院條件 : 口腔顎面外科或耳鼻喉科專科醫師一名及專任口腔病理科或病理專科醫師一名 治療醫院條件 : 口腔顎面外科或耳鼻喉科專科醫師、口腔病理科或病理專科醫師、整形外科專科醫師、放射腫瘤科專科醫師、及腫瘤內科專科醫師至少各一名 ： 註：完整名單可至國民健康局網站癌症防治組查詢

5 口腔癌確認診斷及治療醫院名單(99.04) 台北縣 確診治療 財團法人恩主公醫院 區域醫院 02-26723456
台北縣三峽鎮復興路三九九號 財團法人徐元智先生醫藥基金會附設亞東紀念醫院 台北縣板橋市南雅南路二段二一號 財團法人天主教會耕莘醫院 台北縣新店市中山路三六二號 財團法人佛教慈濟綜合醫院臺北分院 新制優等 乙類教學醫院 台北縣新店市建國路二八九號 確診 台北縣立醫院 地區醫院 台北縣三重市中山路2號 行政院衛生署台北醫院 台北縣新莊市思賢里思源一二七號 國泰綜合醫院汐止分院 新制合格 台北縣汐止市建成路59巷2號 天主教耕莘醫院永和分院 台北縣永和市中興街80號

6 口腔癌確認診斷及治療醫院名單(99.04) 台北市 確診治療 國立台灣大學附設醫院 醫學中心 02-23123456 台北市常德街1號
行政院國軍退除役官兵輔導委員會台北榮民總醫院 台北市石牌路二段二０一號 三軍總醫院 台北市汀州路三段八號 財團法人基督教臨安息日會台安醫院 區域醫院　 台北市八德路2段424號 財團法人馬偕紀念醫院及其淡水分院 台北市中山北路二段九二號 財團法人國泰綜合醫院 台北市仁愛路四段二八０號 財團法人振興復健中心 台北市北投區振興街45號 財團法人新光吳火獅紀念醫院 台北市士林區文昌路九五號 財團法人私立台北醫學大學附設醫院 區域醫院 台北市吳興街252號 台北市立聯合忠孝院區 台北市南港區同德路八七號 台北市立聯合中興院區 台北市大同區鄭州路一四五號 台北市立聯合仁愛院區 台北市大安區仁愛路四段一０號 確診 台北市立聯合陽明院區 台北市士林區雨聲街一０五號 台北市立聯合醫院婦幼院區 台北市中正區福州街12號 台北市立聯合和平院區 台北市中正區中華路2段33號 台北市立萬芳醫院 台北市文山區興隆路3段21號 國軍松山醫院 台北市松山區健康路一三一號 財團法人辜公亮基金會和信治癌中心醫院 台北市北投區立德路一二五號

7 口腔癌及其癌前病變處理流程

8

9 口腔癌篩檢流程圖 口腔癌及其癌前病變篩檢 疑陽性個案 陰性個案 陽性個案 ABC 是 否 有可疑症狀 疑口腔檳榔病變 非口腔檳榔病變
轉介確診醫院 其它疾病 正常 需切片 不需切片 治療建議 衛教 口腔癌及其癌前病變 非口腔癌及其癌前病變 陰性個案 定期追蹤 部份切除 進一步治療或觀察追蹤 陽性個案 完全切除 定期追蹤

10 轉介常見或容易混淆之口腔癌及其癌前病變

11 Outcome Following a Population Screening Programme for Oral Cancer and Precancer in Japan
All adults over the age of 40 years resident in Tokoname city subjects (5885 male, female: mean age 60.7±11.3 years) Oral mucosal lesions in 783 (4.1%) subjects 200 (25.5%) were referred 137 (68.5%) attended for follow up examination in hospital departments by specialists 39 subjects were confirmed as having oral cancer or precancer (2 squamous cell carcinomas, 37 leukoplakias) 40 with lichen planus Oral Oncology 36 (2000) Oral Oncology 36 (2000) 340-6

12 Outcome Following a Population Screening Programme for Oral Cancer and Precancer in Japan
Oral Oncology 36 (2000) 340-6

13 Outcome Following a Population Screening Programme for Oral Cancer and Precancer in Japan
Oral Oncology 36 (2000) 340-6

14 Outcome Following a Population Screening Programme for Oral Cancer and Precancer in Japan
Oral Oncology 36 (2000) 340-6

15 口腔癌癌前病變治療 共識與原則 原則

16 Management of PMD

17 Treatment of Oral Potentially Malignant Disorders
Wide excision of the lesion CO2 laser surgery Photodynamic therapy Cryotherapy

18 Treatment of OSF Non-surgical treatment Surgical treatment
Corticosteroid Hyaluronidase Interferon-g Surgical treatment Graft Split thickness skin graft (STSG) Bucaal fat pad graft Placental membrane Xenograft (TerudermisTM) Flap Nasolabial flap Palatal island flap Superficial Temporal fascia flap Fore arm flap Coronoidectomy and myotomy

19 Treatment of Lichen Planus
Submucous injection of Kenacort A Cryotherapy (Lichenoid leukoplakia)

20 口腔癌治療共識與原則

21 Staging ST-1 Regional Lymph Nodes (N)
2002 American Joint Committee on Cancer (AJCC) TNM Staging System for the Lip and Oral Cavity Primary Tumor (T) TX Primary tumor cannot be assessed T0 No evidence of primary tumor Tis Carcinoma in situ T1 Tumor 2 cm or less in greatest dimension T2 Tumor more than 2 cm but not more than 4 cm in greatest dimension T3 Tumor more than 4 cm in greatest dimension T4(lip) Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin of face (ie, chin or nose) T4a (oral cavity) Tumor invades adjacent structures (eg, through cortical bone, into deep [extrinsic] muscle of tongue [genioglossus, hyoglossus, palatoglossus, and styloglossus], maxillary sinus, skin of face) T4b Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery *Note: Superficial erosion alone of bone/tooth socket by gingival primary is not sufficient to classify as T4. Regional Lymph Nodes (N) NX Regional nodes cannot be assessed N0 No regional lymph node metastasis N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension N2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension N2a Metastasis in single ipsilateral lymph node more than 3cm but not more than 6 cm in greatest dimension N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension N3 Metastasis in a lymph node more than 6 cm in greatest dimension Distant Metastasis (M) MX Distant metastasis cannot be assessed M0 No distant metastasis M1 Distant metastasis ST-1

22 Staging ST-2 Stage Grouping Histologic Grade (G)
Stage 0 Tis N0 M0 GXGrade cannot be Stage I T N0 M assessed Stage II T N0 M G1 Well differentiated Stage III T N0 M G2 Moderately T N1 M differentiated T N1 M G3 Poorly differentiated T N1 M0 Stage IVA T4a N0 M0 T4a N1 M0 T N2 M0 T N2 M0 T N2 M0 T4a N2 M0 Stage IVB AnyT N3 M0 T4b AnyN M0 Stage IVC AnyT AnyN M1 Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York. (For more information, visit ( Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer-Verlag New York, Inc., on behalf of theAJCC. ST-2

23 口腔癌的治療模式 第一期 第二期 第三期 第四期 早期口腔癌 晚期口腔癌 手術治療 手術治療 放射線治療 放射線治療 化學治療 標靶治療

24 Radiotherapy

25 Adjuvant Chemoradiation for Resected High-Risk Disease

26 Concurrent Chemoradiotherapy for Unresectable Head & Neck Cancer

27 Target Therapy for Head & Neck Cancer
Erbitux is a chimaeric monoclonal antibody (MAb) specific for the EGFR. Adapted from Bonner JA, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:

28 Cetuximab

29 The Follow-up Strategy of Oral Cancer
Physical examination: Year 1, every 1-3 mo Year 2, every 2-4 mo Year 3-5, every 4-6 mo >5 yr, every 6-12 mo Chest imaging Annually Or earlier if clinically indicated TSH every 6-12 mo, if neck irradiated.

30 轉介個案之管理

31 Annual Screening for Oral Cancer Detection: Japanese Experience
Cancer Detect Prev 2003;27:333-7.

32 Annual Screening for Oral Cancer Detection: Japanese Experience
Cancer Detect Prev 2003;27:333-7.

33 Annual Screening for Oral Cancer Detection: Japanese Experience
The number of new oral cancers detected in the program was too low to determine the optimal frequency for oral cancer screening but new oral lerkoplkias were found in annual re-screening: the data indicate that the interval between two screens for this population should not be greater than 12 months. Cancer Detect Prev 2003;27:333-7.

34 Annual Screening for Oral Cancer Detection: Japanese Experience
Compliance rates to re-attend were lower in the youngest and oldest age groups. Females were also more likely to re-attend compared with males. Cancer Detect Prev 2003;27:333-7.

35 The Rate and the Time to Transformation in Patients with Potentially Malignant Oral Epithelial Lesions The 1458 patients with histological diagnoses of various premalignant oral lesions were followed up between 1991 and 2001. Within the cohort of 1458 patients, 44 patients progressed to oral cancer in the same site as the initial lesions with an overall transformation rate of 3.02% and a mean follow-up time of months. J Oral Pathol Med 2007;36:25–9.

36 不同口腔癌前病變的惡性轉變率 Hyperkeratosis/epithelial hyperplasia (29.01%)
Submucous fibrosis (27.57%) Verrucous hyperplasia (22.22%). Epithelial dysplasia with hyperkeratosis/epithelial hyperplasia (8.85%) Lichen planus (9.80%) Epithelial dysplasia with submucous fibrosis (2.54%) J Oral Pathol Med 2007;36:25–9.

37 個案管理原則 建立高危險群資料庫 確立癌前病變回診再檢查模式 選擇適當回診時間